Disc Medicine, Inc. (NASDAQ:IRON) Accelerates Toward Potential Approval And Commercial Launch
Disc Medicine moves from program de‑risking into near‑term regulatory readouts, supported by clinical catalysts and a cash position that sustains development. Recent data releases and technical momentum set a conditional bias for upside into early 2026.







